comparemela.com

Latest Breaking News On - Hospital santo ant - Page 1 : comparemela.com

New VEXAS syndrome identified in Portugal

10 registered cases of a new syndrome have been detected in Portugal, two of which resulted in the death of the patient. 

Raquel fariaHospital centerHospital santo antAlto douroHospital de santo ant

Ionis Presents Positive Results From Phase 3 Study Of Eplontersen In Neuropathy Impairment

LONDON (dpa-AFX) - Ionis Pharmaceuticals Inc. (IONS) presented positive results from a planned 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen

Baden wübergCity ofUnited kingdomCentro hospitalar universitTeresa coelhoInternational symposium on amyloidosisIonis pharmaceuticals incDrug administrationMore such health newsInternational symposiumHospital santo ant

Ionis presents positive results from Phase 3 NEURO-TTRansform study at International Symposium on Amyloidosis

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today presented positive results from a planned 35-week interim analysis of the Phase 3.

Baden wübergUnited statesCentro hospitalar universitEugene schneiderTeresa coelhoInternational symposium on amyloidosisDrug administrationIonis pharmaceuticals incExchange commissionIonis pharmaceuticalsInternational symposiumConjugated antisenseHospital santo antLatin americaOrphan drug designationHereditary transthyretin amyloidosis

Ionis announces positive results from a phase 3 study of eplontersen

Ionis and AstraZeneca's eplontersen shows positive results in patients with hereditary transthyretin-mediated amyloid polyneuropathy.

Baden wübergUnited statesCentro hospitalar universitEugene schneiderTeresa coelhoInternational symposium on amyloidosisIonis pharmaceuticals incDrug administrationIonis pharmaceuticalsInternational symposiumNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyConjugated antisenseHospital santo antLatin america

Eplontersen shown to slow disease progression in polyneuropathy patients

Data in the Phase III NEURO-TTRansform study demonstrate eplontersen to have a positive impact on polyneurotherapy progression.

Centro hospitalar universitEugene schneiderTeresa coelhoDrug administrationIonis pharmaceuticalNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyConjugated antisenseNew drug applicationHospital santo ant

vimarsana © 2020. All Rights Reserved.